Heart Valve Repair — Cost, Top Hospitals & Success Rates | MyMedicPlus

When a diseased heart valve is structurally amenable to repair, preservation of the native valve is strongly preferred over replacement with a mechanical or biological prosthesis. This principle — articulated by Professor Alain Carpentier of Paris and endorsed by the 2021 AHA/ACC Valvular Heart Disease Guidelines — is supported by compelling clinical evidence: repair avoids the complications of prosthetic valve implantation (thromboembolism, anticoagulation-related bleeding with mechanical valves, structural valve deterioration with biological valves), preserves the natural subvalvular apparatus that maintains left ventricular geometry and systolic function, and delivers superior long-term haemodynamic performance.

The benefits of repair over replacement are most clearly demonstrated for the mitral valve. At expert centres, isolated posterior mitral leaflet prolapse repair carries an operative mortality under 1%, a 10-year freedom from reoperation of 90–95%, and functional outcomes superior to any prosthesis. For the aortic valve, valve-sparing aortic root replacement (VSARR) preserves the native leaflets during root aneurysm surgery, avoiding lifelong anticoagulation. For the tricuspid valve, ring annuloplasty at the time of left-sided surgery prevents progressive late tricuspid regurgitation that would otherwise develop in 25–30% of patients.

The 2021 AHA/ACC guidelines recommend that patients with severe mitral regurgitation amenable to repair should be referred to heart valve centres of excellence — defined as institutions performing >25 mitral repairs per year with documented repair rates >80% for all comers with degenerative MR. At such centres, repair is achievable in over 95% of patients with isolated posterior leaflet prolapse and 75–85% with anterior leaflet or bileaflet (Barlow) disease. Lower-volume centres may achieve repair in only 40–60% of cases, with correspondingly inferior durability.

Primary (degenerative) mitral regurgitation is the dominant indication for mitral valve repair. The spectrum of degenerative MR includes:

• Posterior leaflet prolapse: The most common subtype; typically involves P2 scallop prolapse due to chordal elongation or rupture. Highly amenable to repair with triangular or quadrangular resection techniques. Repair rates >95% at expert centres.
• Barlow's disease: Myxomatous degeneration involving both leaflets with annular dilation, billowing leaflets, and multiple chordal abnormalities. More complex repair requiring multiple techniques; repair rate 75–85% at expert centres.
• Fibroelastic deficiency: Localised, age-related tissue deficiency with acute chordal rupture; usually posterior leaflet, amenable to limited resection or chordal replacement.
• Commissural prolapse: Involving the posteromedial or anterolateral commissure; treated with commissural resection or neochordal reconstruction.

Secondary (functional) mitral regurgitation: Caused by LV remodelling displacing the papillary muscles, leading to leaflet tethering and incomplete coaptation. Open surgical restrictive annuloplasty with an undersized rigid ring reduces annular area and improves coaptation; however, outcomes are inferior to primary MR repair, with high MR recurrence at 2 years (30–50%). Transcatheter TEER (MitraClip) is increasingly preferred for high-risk surgical patients with secondary MR meeting COAPT criteria.

Aortic regurgitation with root aneurysm: Patients with aortic root dilation (e.g., Marfan syndrome, bicuspid aortopathy, non-familial root aneurysm) with structurally normal or only mildly abnormal aortic leaflets are candidates for valve-sparing aortic root replacement (VSARR), preserving native leaflet function without prosthetic replacement.

Functional and secondary tricuspid regurgitation: Annular dilation (usually in the context of left-sided heart disease, pulmonary hypertension, or longstanding AF) causes functional TR. Tricuspid annuloplasty — placing a ring to reduce and reshape the annulus — corrects functional TR at the time of concomitant mitral or aortic surgery and prevents late TR progression.

Congenital valve disease: Many congenital anomalies (partial atrioventricular septal defects with cleft anterior mitral leaflet, Ebstein anomaly of the tricuspid valve, pulmonary stenosis in selected cases) are amenable to repair, particularly in children and young adults in whom lifelong prosthesis management is especially burdensome.

Determining repair eligibility involves three assessments: anatomical feasibility (can this valve be repaired durably?), haemodynamic timing (is intervention indicated now, or should the patient be monitored?), and surgical risk (what is the operative risk at this institution?).

Anatomical feasibility for mitral repair is assessed by transthoracic and transesophageal echocardiography. TEE provides leaflet morphology, prolapse segment, chordal anatomy, annular dimensions, and degree of coaptation loss. Key factors predicting repairability: single-segment posterior leaflet prolapse (highest repair rate), absence of severe calcification of the leaflets or annulus, adequate leaflet tissue (excess tissue in Barlow favours repair; fibroelastic deficiency with very thin leaflets may limit techniques), and absence of severe rheumatic scarring. 3D TEE and cardiac MRI provide additional anatomical precision. Cardiac CT may be used to assess annular calcification burden.

Carpentier's functional classification guides operative planning: Type I (normal leaflet motion, MR from annular dilation or leaflet perforation — treated by annuloplasty or perforation closure); Type II (leaflet prolapse from chordal elongation/rupture or papillary muscle elongation — treated by resection, transfer, or neochordal repair); Type IIIa (restricted leaflet motion in diastole and systole from rheumatic disease — treated by commissurotomy, leaflet decalcification, chordal fenestration); Type IIIb (restricted systolic motion from papillary muscle displacement in ischaemic/dilated cardiomyopathy — treated by restrictive annuloplasty).

Timing for mitral repair (per 2021 AHA/ACC): Class I — symptomatic severe primary MR (Stage D) with LVEF >30%; asymptomatic severe primary MR with LVEF ≤60% or LVESD ≥40 mm (Stage C2). Class IIa — asymptomatic severe primary MR with high likelihood of durable repair at an experienced centre, even without LV dilation, if operative mortality <1%. This allows early repair — surgery before LV dysfunction develops — which is now supported by evidence showing superior long-term outcomes when repair is performed with LVEF ≥65% compared to waiting until LV dysfunction occurs.

Mitral valve repair — surgical techniques (Carpentier approach):

• Leaflet resection: Quadrangular resection of the prolapsing segment (e.g., P2 prolapse) excises the abnormal leaflet tissue, and the leaflet edges are re-approximated (plication) before annuloplasty. Triangular resection preserves more leaflet tissue and reduces the risk of systolic anterior motion (SAM) of the anterior mitral leaflet. Resection is the oldest and most widely validated technique for posterior leaflet prolapse.
• Artificial neochordae (chordal replacement): Gore-Tex polytetrafluoroethylene (PTFE) sutures are threaded through the papillary muscle head and secured to the prolapsing leaflet free edge at the correct length. This is the preferred technique at many centres for anterior leaflet prolapse (which is less amenable to resection) and is also used for posterior prolapse to preserve leaflet tissue and reduce SAM risk. The 'respect rather than resect' philosophy using neochordae is increasingly popular for all prolapse subtypes.
• Chordal transfer: Secondary (marginal) chords from the posterior leaflet are transposed to support the anterior leaflet — used for anterior leaflet prolapse when native chord transfer is feasible.
• Ring annuloplasty: All mitral repairs must be completed with ring annuloplasty, which reduces the annular circumference to a physiological size, restores annular geometry, and takes tension off the repaired leaflet. Rigid complete rings (Carpentier-Edwards Classic, Physio, Physio II) are preferred for primary MR and provide better annular stabilisation. Semi-rigid rings (Medtronic Profile 3D, St. Jude Tailor) and flexible bands (Duran, Cosgrove-Edwards) are options for functional MR where a more compliant annulus is desired. For functional MR, undersized restrictive annuloplasty with a rigid ring two sizes smaller than anatomical size improves coaptation.
• Additional techniques: Cleft closure (for cleft anterior mitral leaflet in AVSD or isolated anomaly); commissurotomy (for rheumatic MS with anterior commissure fusion); leaflet augmentation with pericardial patch (for extensive fibroelastic deficiency or rheumatic disease with leaflet restriction).

Transcatheter mitral valve repair — TEER: The MitraClip system (Abbott) uses a catheter system delivered via transseptal access under TEE guidance. A V-shaped clip grasps the anterior and posterior mitral leaflet edges at the origin of the regurgitant jet, creating a double-orifice valve (the Alfieri stitch performed percutaneously). The EVEREST II RCT demonstrated non-inferiority to surgery for freedom from death, surgery, and 3+ MR at 1 year in moderate-to-high-risk primary MR patients. The COAPT trial demonstrated that in selected secondary MR patients (LVEF 20–50%, LVESD ≤70 mm) who remained symptomatic on GDMT, MitraClip reduced all-cause mortality by 38% and HF hospitalisation by 47% versus GDMT alone. The PASCAL system (Edwards) uses a wider spacer element and independent leaflet capture.

Aortic valve repair — valve-sparing root replacement: In patients with aortic root aneurysm and structurally normal or near-normal aortic leaflets (typically younger patients with Marfan syndrome or bicuspid aortopathy), the native aortic valve can be preserved while the dilated aortic root is replaced. The two principal techniques are: (1) Yacoub remodelling (1979) — the aortic root is replaced with a tailored Dacron graft creating three neo-sinuses; the native valve is suspended within the graft. More physiological sinus architecture but the annulus is not fixed. (2) David reimplantation (David I, 1992) — the native valve is reimplanted within a cylindrical Dacron tube graft that encircles and stabilises the aortic annulus; this prevents annular dilation. The David procedure has better long-term annular stability, lower AR recurrence rates (<5% moderate+ AR at 10 years in expert hands), and is now the preferred VSARR technique at most centres. Modification of the graft with neo-sinus bulges (Valsalva graft, PEARS technique) may improve leaflet dynamics and durability.

Tricuspid valve repair: Ring annuloplasty is the dominant technique. The tricuspid annulus is predominantly muscular (anterior and posterior segments) with a fibrous component (posteroseptal). Options include: rigid rings (Medtronic Contour 3D, Edwards MC3), semi-rigid rings (St. Jude Tailor Tricuspid), and flexible suture annuloplasty (De Vega — running suture along the annular circumference). For Ebstein anomaly, the cone reconstruction technique (re-attaches the displaced tricuspid leaflets to the true annulus) has replaced older techniques in most paediatric centres, with excellent long-term results.

The clinical advantages of successful valve repair over prosthetic valve replacement are well-documented across multiple outcomes domains.

Avoidance of anticoagulation: Unlike mechanical prostheses, repaired native valves do not require lifelong warfarin. This eliminates the 1–2% annual risk of major bleeding and the 0.5–1% annual risk of thromboembolic stroke associated with long-term anticoagulation. Patients can safely undergo dental procedures, minor surgery, and other interventions without complex anticoagulation management. For young women of childbearing age, repair avoids the teratogenic risks of warfarin during pregnancy.

Preservation of LV geometry and systolic function: The mitral subvalvular apparatus (chordae tendineae and papillary muscles) plays a critical role in maintaining left ventricular spherical geometry and systolic function. Preservation of this apparatus during repair, compared with chord-cutting during mitral replacement, results in better post-operative LVEF (mean 5–8% higher), lower rates of post-operative LV dysfunction, and improved long-term cardiac function. Studies consistently show lower late cardiovascular mortality in repaired patients compared with replaced patients matched for pre-operative characteristics.

Excellent long-term durability: For posterior leaflet prolapse repair at expert centres, 10-year freedom from reoperation exceeds 90–95%. Even for the more complex bileaflet (Barlow) disease, 10-year freedom from reoperation of 85–90% has been reported. Repair durability, unlike biological prostheses, does not follow a predictable deterioration timeline — a successful repair performed at age 50 may last decades without structural deterioration, as the native leaflet tissue continues to function rather than degenerate.

Lower operative mortality: Isolated mitral valve repair at expert centres carries a 30-day mortality of 0.5–1.0%, lower than the 1.5–2.5% for mitral valve replacement. Combined repair + coronary artery bypass grafting has mortality of 2–4% versus 4–6% for replacement + CABG, reflecting the intrinsic haemodynamic advantages of preservation over replacement.

Valve repair, while superior to replacement when feasible, carries procedure-specific risks in addition to the standard risks of cardiac surgery under cardiopulmonary bypass.

Repair failure requiring intraoperative conversion to replacement: Approximately 2–5% of planned mitral repairs require conversion to replacement when the repair does not achieve adequate competence on intraoperative TEE assessment or when the leaflet/chordal anatomy is more abnormal than anticipated. Intraoperative TEE after weaning from bypass is mandatory — residual MR ≥2+ detected on TEE should trigger immediate revision or replacement before chest closure.

Systolic anterior motion (SAM): A complication specific to mitral valve repair in which the anterior mitral leaflet or subvalvular apparatus is displaced anteriorly during systole into the LVEF outflow tract, causing dynamic LVOT obstruction with haemodynamic compromise. SAM occurs in approximately 3–5% of mitral repairs, particularly when: excess posterior leaflet height is not adequately reduced, the C:D ratio (coaptation point to annular distance) is less than 1.3, or the LVOT is anatomically narrow. Management includes volume loading, cessation of inotropes, phenylephrine, and intravenous beta-blocker; persistent SAM may require return to bypass for revision.

Residual or recurrent regurgitation: Late MR recurrence affects 5–15% of repairs at 10 years (higher in functional MR repairs — up to 30–50% recurrence at 2 years). For primary degenerative MR, late recurrence is most commonly due to disease progression in other segments not treated at the initial repair, new chordal rupture, or ring dehiscence.

Standard cardiac surgery risks: Stroke in 1–2%, perioperative atrial fibrillation in 20–40% (usually self-limiting but requiring anticoagulation for 3–6 months), bleeding and re-exploration in 5–10%, acute kidney injury in 3–5%, sternal wound infection in 0.5–1.5%, and prolonged ventilation in 2–5% of patients undergoing mitral repair.

TEER (MitraClip) specific risks: Single-leaflet device attachment (clip grabs one rather than both leaflets, 1–2%); residual significant MR (common — TEER rarely achieves MR elimination but reduces to 1–2+ in most cases); clip embolisation (<0.5%); iatrogenic MV stenosis from over-aggressive clipping (MVA <1.5 cm²); and transseptal puncture complications (pericardial tamponade <1%, aortic root puncture <0.5%).

Aortic valve-sparing repair risks: Late AR recurrence requiring reoperation — approximately 5–15% at 10 years depending on technique, annular stabilisation, and pre-operative leaflet morphology. Bicuspid valves have higher late AR recurrence than trileaflet valves; concurrent aortic cusp repair techniques (geometric ring, raphe resection, cusp augmentation) can reduce but not eliminate recurrence risk.

Post-repair follow-up is structured to detect early repair dysfunction, late recurrence of regurgitation, and new valve-related complications.

Early post-operative assessment: Transthoracic echocardiography (TTE) is performed before hospital discharge (typically day 3–5) and again at 4–6 weeks post-operatively to establish the baseline post-repair result. Mild residual MR (1+) after mitral repair is common and acceptable; moderate (2+) or greater warrants close surveillance and re-referral to a valve specialist. LV dimensions (LVESD, LVEDD) and LVEF are measured — recovery of LVEF is expected over the first 6–12 months as LV remodelling occurs after correction of volume overload.

Long-term echocardiographic surveillance: Per 2021 AHA/ACC guidelines, TTE is recommended at 3–6 months post-repair, at 12 months, and then annually in stable asymptomatic patients. Any new symptoms (worsening dyspnoea, orthopnoea, reduced exercise tolerance) should trigger an unscheduled TTE. TEE is indicated if TTE image quality is inadequate or if a repair complication is suspected.

Anticoagulation after repair: Short-term anticoagulation with warfarin (INR 2.0–3.0) for 3–6 months post-repair is recommended by most centres to cover the early endothelialisation phase of the annuloplasty ring, after which anticoagulation can be discontinued in patients in sinus rhythm. Low-dose aspirin (75–81 mg/day) is typically continued indefinitely. Patients who develop atrial fibrillation post-repair require anticoagulation per AF management guidelines (typically a DOAC unless concomitant mechanical prosthesis).

Infective endocarditis prophylaxis: AHA guidelines recommend antibiotic prophylaxis for dental procedures in patients with prosthetic material (including annuloplasty rings) for 6 months after implantation while the ring surface endothelialises. Thereafter, most repaired native mitral valves do not require routine prophylaxis unless prior endocarditis or residual structural abnormality is present. Patients undergoing VSARR (aortic valve sparing) with a Dacron graft should continue prophylaxis indefinitely due to the prosthetic graft material.

Cardiac rehabilitation: Structured cardiac rehabilitation beginning 4–6 weeks post-operatively improves functional capacity, reduces depression and anxiety, and accelerates return to normal activities. Most patients can return to non-strenuous work within 6–8 weeks and full activity within 3–6 months.

The economics of valve repair reflect both procedure costs and the downstream savings from avoiding prosthesis-related complications — particularly the lifetime costs of anticoagulation, INR monitoring, and haemorrhagic or thromboembolic events associated with mechanical valve replacement.

Surgical mitral valve repair costs: In the United States, isolated mitral valve repair carries average hospital charges of USD 80,000–180,000, with insurance payments typically USD 40,000–80,000. In India, surgical mitral repair at accredited centres (Apollo Hospitals, Narayana Health, Fortis, Medanta) costs USD 5,000–15,000 all-inclusive. In Thailand (Bumrungrad, Samitivej), USD 12,000–22,000. In Germany, EUR 20,000–40,000 (covered by statutory insurance for German residents).

Minimally invasive mitral valve repair — performed via right mini-thoracotomy (4–6 cm incision) using video-assisted or robotic techniques rather than median sternotomy — adds 15–25% to procedural costs but reduces hospital length of stay (3–5 days vs 5–7 days), decreases blood transfusion requirements, and achieves earlier return to activity. Robotic mitral repair (da Vinci system) is available at high-volume centres and is particularly attractive for re-operative cases and anterior leaflet disease.

TEER (MitraClip) costs: The MitraClip device costs USD 20,000–25,000; total procedural costs including hospitalisation are USD 50,000–80,000 in the US. TEER is considerably less expensive than surgical repair for high-risk patients when avoiding a prolonged ICU stay after open surgery is factored in. Outside the US, MitraClip costs USD 15,000–30,000 in Europe and Asia.

Centre selection considerations: Volume-outcome relationships for valve repair are among the strongest in all of cardiac surgery. Centres performing >25 mitral repairs per year achieve repair rates of >90% for degenerative MR and 30-day mortalities of <1%; centres performing fewer than 5 repairs per year achieve repair rates of 40–60% with mortality up to 3–5%. The AHA/ACC Valve Centres of Excellence programme, and equivalent designations in Europe and Asia, identify high-volume, high-quality repair programmes. For elective mitral valve repair, referral to a centre of excellence is explicitly recommended in current guidelines, even if it requires travel.

In patients in whom valve repair is not anatomically achievable or has failed, prosthetic valve replacement provides definitive treatment, albeit with the trade-offs of anticoagulation (mechanical) or limited durability (biological).

Mitral valve replacement (MVR): When repair is not feasible (extensive leaflet calcification, severely restricted rheumatic leaflets, or failed prior repair), replacement with a mechanical (St. Jude Medical Masters Series, CarboMedics) or biological (Carpentier-Edwards Perimount Magna, Hancock II) prosthesis is performed. The decision between mechanical and biological prosthesis is guided by patient age, anticoagulation ability, and preference — detailed in the Heart Valve Replacement article. Mechanical MVR requires INR target 2.5–3.5 (higher thrombogenicity of the mitral position vs aortic). Subvalvular preservation — leaving chordae and papillary muscles intact during replacement — significantly improves post-MVR LV function and survival and is now standard practice.

Transcatheter mitral valve replacement (TMVR): A rapidly evolving field in which a transcatheter prosthesis is deployed within the native mitral annulus via transseptal access. Currently approved only for valve-in-valve (ViV), valve-in-ring (ViR), or valve-in-mitral annular calcification (ViMAC) applications using TAVR technologies (Edwards SAPIEN 3). Dedicated TMVR systems (Tendyne, Intrepid, Highlife) are in clinical trials for native annulus implantation and show promise for patients with severe MAC or failed prior MVR who are ineligible for open surgery.

Medical management with watchful waiting: For asymptomatic patients with severe primary MR and preserved LV function (LVEF >60%, LVESD <40 mm), watchful waiting with 6–12 monthly echocardiography is a guideline-supported option. ACE inhibitors do not reduce MR progression in asymptomatic primary MR and are not indicated for this purpose; beta-blockers reduce LV remodelling in secondary MR within HFrEF. Serial monitoring allows timely intervention before LV dysfunction occurs, maintaining the benefits of early repair.